Oncology Best Practice™: Evolving Applications of Immuno-Oncology Strategies: New Approaches, New Combinations, and New Ways to Care for Lung, Head and Neck, and Bladder Cancers
Past Events

Accreditation/
Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this live activity for 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hour.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from AstraZeneca.

Oncology Best Practice™: Evolving Applications of Immuno-Oncology Strategies: New Approaches, New Combinations, and New Ways to Care for Lung, Head and Neck, and Bladder Cancers


In order to request this CME/CE activity for your center, please contact Samantha Miller at Smiller@gotoper.com or call (609) 325-4808
 

Oncology Best Practice™:
Evolving Applications of Immuno-Oncology Strategies: New Approaches, New Combinations, and New Ways to Care for Lung, Head and Neck, and Bladder Cancers
August 2017- December 2017

Click Here to View Upcoming Events

Overview:

The emergence of immuno-oncology strategies to treat cancer has transformed the way clinicians think about solid tumor management. Among these tumors, lung cancer, head and neck cancer, and bladder cancer have become a major focus of investigational efforts in immuno-oncology research due to substantial unmet clinical needs and evidence demonstrating the clinical potential of these approaches. In addition to single-agent immunotherapy, the use of novel immuno-oncology combinations is generating interest and rational clinical trial designs are combining immunotherapy with a wide range of partner therapeutics, with the goal of inducing profound and durable responses. Further, the speed at which information continues to emerge in the immuno-oncology space is creating practice and educational gaps for oncology clinicians who strive to maintain state-of-the-art care for their patients.

To address these educational and therapeutic needs, this Oncology Best Practice™ series will feature internationally renowned experts in immuno-oncology who will discuss key emerging clinical data sets, the role of evolving biomarkers, and how to safely apply immunotherapy to a wide variety of malignancies. Held in leading cancer centers, large oncology practice groups, and community hospitals throughout the United States, these 1-hour interactive meetings will address therapeutic needs that persist for patients with cancer, followed by current and emerging immunotherapies to address these medical needs. Ample discussion time will allow participants to interact with expert faculty to address challenges in their practice.

Key topics to be addressed by faculty include:

  • Practice-changing data with immunotherapy in lung, head and neck, and bladder cancers
  • Current approaches to biomarkers and patient selection
  • Recognizing and managing unique adverse events with immunotherapy
  • Emerging data with new immunotherapy approaches

Target Audience

This educational activity is directed toward medical oncologists. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of cancer are invited to attend.

In order to request this CME/CE activity for your center, please contact Glen Fratengelo at gfratengelo@gotoper.com

Educational Objectives

Upon completion of this activity, participants will be better prepared to:

  • Detail specific anti–CTLA-4, anti–PD-1, and anti–PD-L1 mechanistic approaches in the context of their developmental rationale to target solid tumors
  • Apply evidence on single-agent/combination immuno-oncology strategies and explain its impact on decision making in the evolving fields of lung cancer, head and neck cancer, and bladder cancer
  • Delineate practical methods to individualize the application of immuno-oncology strategies based on PD-L1 testing results
  • Develop multidisciplinary actions steps to proactively mitigate the impact of immune-related adverse events among patients who receive checkpoint inhibitors for the treatment of non–small cell lung cancer, head and neck cancer, and bladder cancer

Chair:

Roy Herbst, MD, PhD
Ensign Professor of Medicine (Medical Oncology)
Professor of Pharmacology
Chief of Medical Oncology
Associate Director for Translational Research
Yale Cancer Center
Yale School of Medicine
New Haven, CT


Calendar of Events
SUNMONTUESWEDTHURSFRISAT
  12345
6789101112
13141516171819
20212223242526
2728293031
Filter By